Bausch + Lomb Corporation (BLCO) has released an update.
Bausch + Lomb Corporation announced the success of their clinical study on Blink™ NutriTears®, a new daily supplement designed to alleviate dry eye symptoms. The study confirmed the supplement’s effectiveness in improving tear production and reducing ocular symptoms, marking it as a promising solution for the millions affected by dry eyes. Set for a Q3 release in 2024, Blink NutriTears® offers hope for those suffering from this common condition, particularly among younger adults increasingly impacted due to digital screen use and other modern stressors.
For further insights into BLCO stock, check out TipRanks’ Stock Analysis page.
